Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent expiration for Sumitomo Pharma drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 64

Drugs Marketing 64

Drug Patent Watch

JANUARY 27, 2024

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs 59

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for LINZESS Linzess is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are twelve patents protecting… The post New patent expiration for Abbvie drug LINZESS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for RIVIVE Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. It is available from one supplier. There is one… The post New patent for Harm Reduction drug RIVIVE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59